Hepatitis a vaccine - Biologic Drug Details

Summary for hepatitis a vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	3
Recent Clinical Trials:	See clinical trials for hepatitis a vaccine

Recent Clinical Trials for hepatitis a vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Phichit Provincial Public Health Office, Ministry of Public Health, Thailand (Host institution)	PHASE4
Liver Foundation Thailand	PHASE4
The Task Force for Global Health	PHASE4

See all hepatitis a vaccine clinical trials

Pharmacology for hepatitis a vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Hepatitis A Virus Vaccine
Chemical Structure	Hepatitis A Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hepatitis a vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hepatitis a vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for hepatitis a vaccine Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Hepatitis A Vaccine

Last updated: February 26, 2026

What Are the Key Market Drivers for Hepatitis A Vaccines?

The global hepatitis A vaccine market is influenced by several factors:

• Rising Incidence: Globally, approximately 1.5 million cases of hepatitis A are reported annually, primarily in developing countries with poor sanitation [1].
• Immunization Programs: Governments in North America and Europe have incorporated hepatitis A vaccines into routine immunization schedules for children, increasing demand.
• Travel Tourism: Increased international travel to endemic regions sustains demand for pre-travel vaccinations.
• Outbreaks and Public Health Policies: Local outbreaks prompt mass immunization campaigns, boosting short-term sales.
• Shift Toward Combination Vaccines: The integration of hepatitis A with other vaccines (e.g., hepatitis B, typhoid) expands market offerings and increases vaccine uptake.

Who Are the Major Players and Their Market Shares?

The market is concentrated among several pharmaceutical companies:

• GSK: Holds approximately 60% of the global hepatitis A vaccine market. Their vaccine, Havrix, has a high global distribution volume.
• Merck: Markets Vaqta, with an estimated 25% share, primarily in the U.S.
• Others: Includes manufacturers like BI (Biologics Inc.), which caters to emerging markets but holds less than 15% combined.

What Are the Market Segments and Geographies?

Geographic Distribution

• North America: Largest market, driven by routine immunization, travel, and outbreak response.
• Europe: Increasing demand due to travel and improved immunization programs.
• Asia-Pacific: Fastest growth, due to large populations, urbanization, and expanding immunization initiatives.
• Latin America and Middle East: Growth driven by outbreak responses and travel-related demand.

Market Segments

• Adult Population: Increasing use for travelers and outbreak control.
• Pediatric Population: Inclusion in routine childhood immunization programs in many countries.
• Combination Vaccines: Growing segment offering enhanced convenience and coverage.

How Is the Financial Trajectory Shaping?

Revenue Projections

• Estimated global hepatitis A vaccine market size was approximately $600 million in 2022.
• Compound annual growth rate (CAGR) forecasted at 6% from 2023 to 2030, reaching $1 billion by 2030 [2].

Profit Margins and Pricing

• Average vaccine price varies by region:
  • North America: ~$30 per dose.
  • Emerging markets: ~$10 per dose.
• GSK’s Havrix reported gross margins of approximately 70% in 2022, reflecting high demand and established manufacturing.

Investment Trends

• R&D investments target improved formulations, such as single-dose capsules and thermostability.
• Partners are exploring thermostable vaccines for distribution in regions with cold chain limitations.
• Merck and GSK have announced pipeline expansions, signaling potential revenue growth.

Challenges Impacting Financial Outlook

• Vaccine Hesitancy: Growing skepticism may slow uptake.
• Pricing Pressures: Governments and insurance providers seek cost reductions, potentially compressing margins.
• Patent Expirations: Limited, but could open generic competition in some markets post-2030.
• Regulatory Approvals: Delays or denials for new formulations impact revenue forecasts.

What Is the Impact of the COVID-19 Pandemic?

The COVID-19 pandemic temporarily disrupted vaccine supply chains and deployment. However, heightened awareness of vaccines facilitated increased demand for immunizations, including hepatitis A. The pandemic also spurred investments in vaccine technology, improving manufacturing efficiencies.

How Do Competitive Strategies Shape Market Outcomes?

• Pricing Strategies: Lower-cost options in emerging markets help expand market share.
• Partnerships: Collaborations with local distributors enhance penetration.
• Product Innovation: Development of combination vaccines attracts broader patient groups and extends patent protection.

Key Metrics and Data Points

Indicator	Value	Source
Global hepatitis A vaccine market size (2022)	$600 million	[2]
Estimated CAGR (2023-2030)	6%	[2]
Market share of GSK (Havrix)	60%	[3]
Market share of Merck (Vaqta)	25%	[3]
Average vaccine price (North America)	$30 per dose	[4]
Typical pediatric dose in immunization programs	2 doses	[1]

Future Outlook

Growth will likely be fueled by expanding immunization in Asia-Pacific, emergency outbreak responses, and innovation toward thermostable formulations. Competition may intensify with new entrants targeting emerging markets, but incumbent firms’ established distribution networks and patent portfolios provide ongoing advantages.

Key Takeaways

• The hepatitis A vaccine market is valued at approximately $600 million and is projected to grow at a CAGR of 6% through 2030.
• GSK maintains dominant market share with Havrix; Merck’s Vaqta is a significant competitor.
• Growth drivers include immunization programs, travel-related demand, and outbreak responses, especially in developing regions.
• Pricing strategies, combination vaccine developments, and technological innovations will influence market dynamics and profitability.
• Regulatory and societal factors, including vaccine hesitancy and cold chain logistics, pose risks to forecasted growth.

FAQs

1. What are the main factors driving hepatitis A vaccine demand?
Immunization policies, international travel, outbreak control, and rising disease prevalence in developing countries.

2. How does regional vaccine pricing affect market growth?
Lower prices in emerging markets expand access, boosting sales volumes but potentially reducing margins.

3. What innovations are expected in hepatitis A vaccine technology?
Single-dose formulations, thermostability, and combination vaccines to enhance compliance and logistics.

4. How might patent expirations influence the market?
Limited post-2030 patent expirations could lead to increased generic competition, lowering prices.

5. What role does government regulation play in market expansion?
Regulatory approvals and inclusion in national immunization schedules are crucial for market penetration.

References

[1] WHO. (2022). Hepatitis A vaccines: WHO position paper. World Health Organization.
[2] MarketsandMarkets. (2023). Hepatitis vaccines market forecast.
[3] Pharma Intelligence. (2023). Key players in hepatitis A vaccine market.
[4] IMS Health. (2022). Vaccine pricing analysis.